Gelesis obesity treatment studies well, but critics still wary; Flamel's once-a-week exenatide garners positive preclinical results;

> Gelesis released data this week showing that its obesity treatment was effective, but a critic at The New York Times panned the result as "modest." Story

> Flamel Technologies demonstrated positive results in a preclinical trial of once-a-week exenatide for Type 2 diabetes. Release

> A study that sheds light on the structure of milk during digestion could lead to the development of a new drug delivery technique. More

> New drug delivery company EastGate Acquisitions pulled in a research grant from Ontario Brain Institute. Release

Suggested Articles

Nanoform Finland tapped Quotient Sciences to help run the first in-human trial of a drug developed using its 'nanoforming' technology later this year.

Swiss scientists are using ultrasound to trap and deliver drugs in the brain, a non-invasive delivery method that could help target tumors, too.

Alexion's 100 mg/ml Ultomiris formulation is expected to slash infusion times by about 60% and bodes well for a planned subcutaneous version, too.